Curia unveils mRNA solution

By The Science Advisory Board staff writers

December 22, 2021 -- Curia, a contract research, development, and manufacturing organization, unveiled its mRNA solution. The new offering includes discovery, process development, and mRNA drug substance production through large-scale lipid manufacturing, lipid nanoparticle formulation, and development for full-scale, sterile, fill-finish services, the company said.

Curia's mRNA-based products span various therapeutic areas, including cancer, heart disease, and chronic illnesses, in addition to its current application in vaccines.

If you like this content, please share it with a colleague!

Related Reading

Curia finalizes LakePharma acquisition
Curia has finalized its acquisition of LakePharma, a privately held biologics drug discovery, clinical research, and manufacturing organization.

Curia to expand manufacturing capacity
Curia plans to expand its commercial manufacturing capacity at its facility in Rensselaer, NY, and is investing more than $35 million in the expanded...

Curia to acquire Integrity Bio
Curia, formerly known as Albany Molecular Research, has inked a definitive agreement to acquire drug formulation and fill-finish provider Integrity Bio.

AMRI rebrands as Curia
Albany Molecular Research (AMRI) has changed its name to Curia, effective July 12.